Biologic Medications for Psoriasis, HS, AD, PN, CSU, and BP
Download our free biologics Quick Reference Chart for dermatology
Updated: August 07, 2026
Quick Reference Chart
This table is not intended to replace medical judgment.
Brand Name | Generic Name | Ages | Loading Dose | Maintenance Dose | Mechanism of Action |
|---|---|---|---|---|---|
| PSORIASIS | |||||
Enbrel* | Etanercept | PsA 18 yrs +
PsO 4 yrs + | 50 mg twice weekly for 12 wks | 50 mg q wk | TNF-α blocker |
PEDS: 0.8 mg/kg q wk (max-dose 50 mg q wk) | |||||
Humira* | Adalimumab | PsO / PsA 18 yrs + | 80 mg on Day 1 and then
40 mg on Day 8 | 40 mg q2 wks | TNF-α blocker |
Remicade* | lnfliximab | PsO / PsA 18 yrs + | 5 mg/kg IV wk 0, 2, and 6 | 5 mg/kg IV q8 wks | TNF-α blocker |
Cimzia* | Certolizumab Pegol | PsO / PsA 18 yrs + | >90 kg: no loading dose | 400 mg q2 wks | TNF-α blocker |
≤90 kg: 400 mg at wk 0, 2 and 4 | 200 mg q2 wks | ||||
Bimzelx* | Bimekizumab | PsO / PsA 18 yrs + | 320 mg at wk 0, 4, 8, 12, and 16 | 320 mg q8 wks (for patients ≥ 120 kg, consider 320 mg q4 wks after wk 16) | IL-17A and F antagonist |
Cosentyx* | Secukinumab | PsA 2 yrs +
PsO 6 yrs + | 300 mg SQ at wk 0, 1, 2, 3, and 4 | 300 mg SQ q4 wks | IL-17A antagonist |
PEDS: Dosage based on body weight and administered at wks 0, 1, 2, 3, and 4 and q4 wks <50 kg = 75 mg | ≥50 kg = 150 mg | |||||
Taltz* | lxekizumab | PsA 18 yrs +
PsO 6 yrs + | 160 mg at wk 0, then 80 mg at wk 2, 4, 6, 8, 10, and 12 | 80 mg q4 wks | IL-17A antagonist |
PEDS: >50 kg = 160 mg at wk 0 then 80 mg q4 wks | 25 to 50 kg = 80 mg at wk 0 then 40 mg q4 wks | <25 kg = 40 mg at wk 0 then 20 mg q4 wks | |||||
Siliq | Brodalumab | PsO 18 yrs + | 210 mg at wk 0, 1, and 2 | 210 mg q2 wks | IL-17A receptor antagonist |
Stelara* | Ustekinumab | PsA 6 yrs +
PsO 6 yrs + | ≤100 kg: 45 mg at wk 0 and 4 | 45 mg q12 wks | IL-12 and IL-23 antagonist |
>100 kg: 90 mg at wk 0 and 4 | 90 mg q12 wks | ||||
PEDS: Weight-based dosing recommended at initial dose, 4 weeks later, then q12 weeks. Less than 60 kg = 0.75 mg/kg | 60 kg to 100 kg = 45 mg | Greater than 100 kg = 90 mg | |||||
Tremfya* | Guselkumab | PsO / PsA 6 yrs + (weighing ≥40 kg) | 100 mg at wk 0 and 4 | 100 mg q8 wks | IL-23 antagonist |
llumya | Tildrakizumab | PsO 18 yrs + | 100 mg at wk 0 and 4 | 100 mg q12 wks | IL-23 antagonist |
Skyrizi* | Risankizumab | PsO / PsA 6 yrs + | 150 mg at wk 0 and 4 | 150 mg q12 wks | IL-23 antagonist |
PEDS: Dosage based on body weight and administered at wks 0 and 4, then q12 wks. <40 kg = 55 mg | ≥40 kg = 150 mg | |||||
Spevigo (GPP) | Spesolimab | 12 yrs + (weighing ≥40 kg) | For treatment of flare: 900 mg IV
Not experiencing a flare: 600 mg SQ | For treatment of flare: Repeat in one week if flare persists
Not experiencing a flare: 300 mg SQ q4 weeks
(SQ use after IV dose for flare treatment: Initiate or reinitiate at 300 mg SQ q4 weeks; no loading dose req’d) | IL-36 receptor antagonist |
| HIDRADENITIS SUPPURATIVA | |||||
Humira | Adalimumab | 12 yrs + | Day 1: 160 mg (given in one day or split over 2 consecutive days); Day 15: 80 mg; Day 29: 40 mg q wk or 80 mg q2 wk | 40 mg q wk or 80 mg q2 wks | TNF-α blocker |
PEDS: 30 kg to <60 kg: Day 1: 80 mg; Day 8: 40 mg TNF-α blocker >60 kg: Day 1: 160 mg (given in one day or split over 2 consecutive days); Day 15: 80 mg; Day 29 and subsequent doses: 40 mg q wk or 80 mg q2 wks | PEDS: 30 kg to <60 kg: 40 mg q2 wks >60 kg: 40 mg q wk or 80 mg q2 wks | ||||
Cosentyx | Secukinumab | 12 yrs + | 300 mg at wk 0, 1, 2, 3, and 4 | 300 mg q4 wks; if inadequate response 300 mg q2 wks may be considered | IL-17A antagonist |
PEDS: Dosage based on body weight and administered at wks 0, 1, 2, 3, and 4, then q4 wks ≥30 kg to <90 kg=150 mg ≥90 kg=300 mg | |||||
Bimzelx | Bimekizumab | 18 yrs + | 320 mg at wk 0, 2, 4, 6, 8, 10, 12, 14, and 16 | 320 mg q4 wks | IL-17A and F antagonist |
| ATOPIC DERMATITIS | |||||
Dupixent | Dupilumab | 6 mos + | 600 mg | 300 mg SQ q2 wk | IL-4 receptor-α antagonist (inhibits IL-4 and IL-13) |
PEDS 6m–5y: 5 to <15 kg = 200 mg q4 wks | 15 to <30 kg = 300 mg q4 wks PEDS 6y–17y: 15 to <30 kg = 600 mg then 300 mg q4 wks | 30 to <60 kg = 400 mg then 200 mg q2 wks | ≥60 kg = 600 mg then 300 mg q2 wks | |||||
Ebglyss | Lebrikizumab | 12 yrs + (weighing ≥40 kg) | 500 mg at wk 0 and 2, then 250 mg q2 wks until 16 wks or later, when adequate clinical response is achieved | 250 mg q4 wks or 250 mg q8 wks | IL-13 antagonist |
Adbry | Tralokinumab | 12 yrs + | Adults: 600 mg | Adults: 300 mg q2 wks; after 16 wks, q4 wks may be considered for adults <100 kg who achieve clear or almost clear skin | IL-13 antagonist |
PEDS 12y-17y: 300 mg | PEDS 12y-17y: 150 mg q2 wks | ||||
Nemluvio | Nemolizumab | 12 yrs + | 60 mg | 30 mg q4 wks; for patients achieving clear or almost clear skin at 16 wks, 30 mg q8 wks recommended. Use with topical corticosteroids and/or topical calcineurin inhibitors. When the disease has sufficiently improved, discontinue use of topical therapies | IL-31 receptor antagonist |
| PRURIGO NODULARIS | |||||
Dupixent | Dupilumab | 18 yrs + | 600 mg | 300 mg q2 wks | IL-4 receptor-α antagonist (inhibits IL-4 and IL-13) |
Nemluvio | Nemolizumab | 18 yrs + | 60 mg | Adults weighing ≥90 kg: 60 mg q4 wks
Adults weighing <90 kg: 30 mg q4 wks | IL-31 receptor antagonist |
| CHRONIC SPONTANEOUS URTICARIA | |||||
Xolair | Omalizumab | 12 yrs + | None | 150 mg or 300 mg q4 wks | anti-IgE antibody |
Dupixent | Dupilumab | 2 yrs + | 600 mg | 300 mg q2 wks | IL-4 receptor-α antagonist (inhibits IL-4 and IL-13) |
PEDS 2y-5y: None PEDS 6y-17y: 15 to <30 kg = 600 mg | 30 to <60 kg = 400 mg | ≥60 kg: 600 mg | PEDS 2y-5y: 5 to <15 kg = 200 mg q4 wks | 15 to <30 kg = 300 mg q4 wks PEDS 6y-17y: 15 to <30 kg = 300 mg q4 wks | 30 to <60 kg = 200 mg q2 wks | ≥60 kg: 300 mg q2 wks | ||||
| BULLOUS PEMPHIGOID | |||||
Dupixent | Dupilumab | 18 yrs + | 600 mg | 300 mg q2 wks; use in combination with tapering course of oral corticosteroids | IL-4 receptor-α antagonist (inhibits IL-4 and IL-13) |
SQ = subcutaneous, q = every, wk/W = weeks,
PsO = psoriasis, PsA = psoriatic arthritis, PEDS = pediatric dosing,
GPP = generalized pustular psoriasis
PN = prurigo nodularis
CSU=chronic spontaneous urticaria
BP = bullous pemphigoid
*FDA approved to treat both psoriasis and psoriatic arthritis.
DISCLAIMER: The dosages seen in this chart were obtained from the respective FDA approved package inserts for psoriasis, hidradenitis suppurativa, atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. This chart is for reference only and not to be substituted for clinical judgment. The authors are not responsible for treatment decisions or outcomes based on the information in this chart.
v12 - June 2026 – Copyright 2026 Mark Lebwohl, MD and Nicholas Brownstone, MD.